Senior Associate, Financial Planning & Analysis
Boost your chances before you apply.
Delcath Systems Inc
US
Summary
The Senior Associate will manage budgeting, forecasting, and financial reporting processes while leading the implementation of a new FP&A software platform. They will also partner with cross-functional teams to analyze financial data, identify variances, and streamline recurring processes.
Job Description
|
Job Title: |
Senior Associate, Financial Planning & Analysis |
|
Department: |
Finance |
|
Location: |
Remote |
|
Reports To: |
Director, FP&A |
|
Date Prepared: |
August 2026 |
POSITION SUMMARY
We are seeking a detail-oriented and analytical Senior Associate to join our Financial Planning & Analysis team. This role is central to the organization's budgeting, forecasting, and financial reporting processes, and will play a key part in the rollout of a new FP&A software platform. The ideal candidate combines strong technical and analytical skills with clear communication and a proactive, process-improvement mindset.
PRIMARY DUTIES AND RESPONSIBILITIES:
- Prepare monthly budget-to-actuals analysis, identifying and explaining key variances to business partners and leadership.
- Support commercial forecasting efforts by analyzing sales trends, pipeline data, and market drivers in partnership with the commercial team.
- Assist in the development of the annual operating budget, coordinating timelines, templates, and inputs across departments.
- Support the preparation of quarterly forecasts, including data consolidation, trend analysis, and variance commentary.
- Help lead implementation of the organization's new FP&A software platform, including data migration, process design, testing, and user training.
- Build and maintain financial models and reporting templates to improve accuracy and efficiency of the planning cycle.
- Partner with accounting, commercial, and operations teams to ensure consistent, reliable financial data.
- Identify opportunities to streamline and automate recurring FP&A processes.
QUALIFICATIONS
To perform this job successfully, an individual must be able to perform each essential duty satisfactorily. The requirements listed below are representative of the knowledge, skill, and/or ability required. Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions.
EDUCATION and/or EXPERIENCE
- Bachelor's degree in Finance, Accounting, Economics, or a related field.
- 3–5 years of experience in FP&A, corporate finance, or a related analytical role.
- Advanced Excel skills; experience with FP&A or EPM software (e.g., Adaptive Insights, Anaplan, OneStream, Vena) strongly preferred.
- Strong analytical and problem-solving skills with high attention to detail.
- Excellent communication skills, with the ability to translate financial data for non-finance stakeholders.
- Experience supporting system implementations or process improvement initiatives is a plus.
- Ability to manage multiple deadlines in a fast-paced environment.
LANGUAGE SKILLS
Ability to read and interpret documents such as technical journals, safety rules, operating and maintenance instructions, and procedure manuals. Ability to write routine reports and correspondence. Ability to speak effectively with employees and outside organizations
PHYSICAL DEMANDS
The physical demands described here are representative of those that must be met by an employee to successfully perform the essential functions of this job. Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions.
While performing the duties of this job, the employee is regularly required to sit, stand or walk and talk or hear. The employee is frequently required to use hands to finger, handle, or feel and reach with hands and arms; and is subject to repetitive motions of the wrists, hands, and/or fingers. The employee must occasionally lift and/or move up to 10 pounds. Specific vision abilities required by this job include close vision, distance vision, peripheral vision, depth perception, and ability to adjust focus.
WORK ENVIRONMENT
The work environment characteristics described here are representative of those an employee encounters while performing the essential functions of this job. Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions.
Delcath Systems, Inc. (NASDAQ- DCTH) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. Our proprietary product---Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure.
Delcath is in late-stage clinical development in the United States with initial commercial activities in Europe, where the Melphalan/HDS is marketed as a CE Marked device under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). Our commercial strategy for CHEMOSAT is to steadily grow clinical adoption in major European markets and utilize physician experience to support appeals for reimbursement. Since launch over 250 CHEMOSAT treatments have been performed at over 20 leading European cancer centers. In 2016, we launched our FOCUS Pivotal Study in Hepatic Dominant Ocular Melanoma, and are investigating orphan indications in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. We believe Melphalan/HDS is uniquely positioned to treat the entire liver as a stand-alone or complementary therapy.
Founded
1987
Company size
51-200 employees
Industry
Pharmaceutical Manufacturing
Org type
Public Company
Headquarters
New York, NY
Delcath Systems, Inc. (NASDAQ- DCTH) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. Our proprietary product---Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure.
Delcath is in late-stage clinical development in the United States with initial commercial activities in Europe, where the Melphalan/HDS is marketed as a CE Marked device under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). Our commercial strategy for CHEMOSAT is to steadily grow clinical adoption in major European markets and utilize physician experience to support appeals for reimbursement. Since launch over 250 CHEMOSAT treatments have been performed at over 20 leading European cancer centers. In 2016, we launched our FOCUS Pivotal Study in Hepatic Dominant Ocular Melanoma, and are investigating orphan indications in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. We believe Melphalan/HDS is uniquely positioned to treat the entire liver as a stand-alone or complementary therapy.
Founded
1987
Company size
51-200 employees
Industry
Pharmaceutical Manufacturing
Org type
Public Company
Headquarters
New York, NY